Gilead director sells 5,000 shares after option exercise

Q: How many GILD shares did Jeffrey Bluestone sell and at what prices?

Jeffrey Bluestone sold 5,000 shares of GILEAD SCIENCES, INC. common stock at prices ranging from $143.31 to $146.36 per share on August 20, 2026, in several separate transactions.

Q: What were the stock option exercise prices in the GILD Form 4 for Jeffrey Bluestone?

He exercised non-qualified stock options for 4,665 shares at an exercise price of $67.45 per share and for 335 shares at an exercise price of $61.35 per share, totaling 5,000 shares exercised.

Q: What type of options did Jeffrey Bluestone exercise in the GILD filing?

He exercised Non-qualified Stock Options (Right to Buy) that were fully vested, including an option granted May 12, 2021 and an option granted May 5, 2022, each convertible into Gilead common stock.

GILEAD SCIENCES, INC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GILEAD SCIENCES, INC. (GILD) director Jeffrey Bluestone reported option exercises and related share sales. On August 20, 2026 he exercised non-qualified stock options for a total of 5,000 shares of common stock at exercise prices of $67.45 and $61.35 per share, from fully vested grants dating to 2021 and 2022. He then sold the 5,000 resulting common shares in multiple trades at prices between $143.31 and $146.36 per share pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,000 shares ($390K approx. pre-tax spread)

Exercise and Sale 12 txns

Insider Bluestone Jeffrey

Role Director

Sold 5,000 shs ($725K)

Approx. gross sale proceeds $725K

Approx. exercise cost $335K

Approx. pre-tax spread $390K

Type	Security	Shares	Price	Value
Exercise	Non-qualified Stock Option (Right to Buy) ^{F1, F5}	4,665	$0.00	$0.00
Exercise	Non-qualified Stock Option (Right to Buy) ^{F1, F6}	335	$0.00	$0.00
Exercise	Common Stock ^F1	1,165	$67.45	$79K
Sale	Common Stock ^{F1, F2}	1,165	$143.7543	$167K
Exercise	Common Stock ^F1	1,816	$67.45	$122K
Sale	Common Stock ^{F1, F3}	1,816	$144.9248	$263K
Exercise	Common Stock ^F1	1,658	$67.45	$112K
Sale	Common Stock ^{F1, F4}	1,658	$145.7286	$242K
Exercise	Common Stock ^F1	26	$67.45	$2K
Sale	Common Stock ^F1	26	$146.36	$4K
Exercise	Common Stock ^F1	335	$61.35	$21K
Sale	Common Stock ^F1	335	$146.26	$49K

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 11,395 contracts (Direct); Common Stock — 10,066 shares (Direct)

Footnotes (6)

F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.
F2. Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3. Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F4. Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F5. 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.
F6. 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.

Key Figures

Shares sold: 5,000 shares Option shares exercised: 5,000 shares Exercise price: $67.45 per share +3 more

6 metrics

Shares sold 5,000 shares Common Stock sold on August 20, 2026

Option shares exercised 5,000 shares Non-qualified Stock Options exercised on August 20, 2026

Exercise price $67.45 per share Non-qualified Stock Option expiring May 12, 2031

Exercise price $61.35 per share Non-qualified Stock Option expiring May 5, 2032

Sale price range $143.31–$146.36 per share Common Stock sales on August 20, 2026

10b5-1 plan adoption date May 20, 2026 Rule 10b5-1 trading plan covering the reported transactions

Key Terms

Rule 10b5-1 trading plan, Non-qualified Stock Option (Right to Buy), Exercise or conversion of derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported ... is made pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Non-qualified Stock Option (Right to Buy) financial

"security_title: Non-qualified Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GILD director Jeffrey Bluestone report?

Jeffrey Bluestone reported exercising non-qualified stock options for 5,000 GILD shares on August 20, 2026 and selling the resulting 5,000 common shares the same day in multiple transactions.

How many GILD shares did Jeffrey Bluestone sell and at what prices?

Jeffrey Bluestone sold 5,000 shares of GILEAD SCIENCES, INC. common stock at prices ranging from $143.31 to $146.36 per share on August 20, 2026, in several separate transactions.

What were the stock option exercise prices in the GILD Form 4 for Jeffrey Bluestone?

He exercised non-qualified stock options for 4,665 shares at an exercise price of $67.45 per share and for 335 shares at an exercise price of $61.35 per share, totaling 5,000 shares exercised.

Were Jeffrey Bluestone’s GILD trades made under a Rule 10b5-1 plan?

Yes. The Form 4 states the reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026, and the Rule 10b5-1 checkbox is affirmed.

What type of options did Jeffrey Bluestone exercise in the GILD filing?

He exercised Non-qualified Stock Options (Right to Buy) that were fully vested, including an option granted May 12, 2021 and an option granted May 5, 2022, each convertible into Gilead common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/21/2026 - 07:22 PM EDT Accepted by SEC EDGAR 08/21/2026 - 07:22 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bluestone Jeffrey

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/20/2026		M⁽¹⁾		1,165	A	$67.45	11,231	D
Common Stock	08/20/2026		S⁽¹⁾		1,165	D	$143.7543⁽²⁾	10,066	D
Common Stock	08/20/2026		M⁽¹⁾		1,816	A	$67.45	11,882	D
Common Stock	08/20/2026		S⁽¹⁾		1,816	D	$144.9248⁽³⁾	10,066	D
Common Stock	08/20/2026		M⁽¹⁾		1,658	A	$67.45	11,724	D
Common Stock	08/20/2026		S⁽¹⁾		1,658	D	$145.7286⁽⁴⁾	10,066	D
Common Stock	08/20/2026		M⁽¹⁾		26	A	$67.45	10,092	D
Common Stock	08/20/2026		S⁽¹⁾		26	D	$146.36	10,066	D
Common Stock	08/20/2026		M⁽¹⁾		335	A	$61.35	10,401	D
Common Stock	08/20/2026		S⁽¹⁾		335	D	$146.26	10,066	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Option (Right to Buy)	$67.45	08/20/2026		M⁽¹⁾			4,665	⁽⁵⁾	05/12/2031	Common Stock	4,665	$0	0	D
Non-qualified Stock Option (Right to Buy)	$61.35	08/20/2026		M⁽¹⁾			335	⁽⁶⁾	05/05/2032	Common Stock	335	$0	11,395	D

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

2. Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

4. Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

5. 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.

6. 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.

Remarks:

	/s/ Amy Kim by Power of Attorney for Jeffrey A. Bluestone	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR